AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABBV advanced for three days, in of 365 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on ABBV as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on May 28, 2025. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
ABBV moved below its 50-day moving average on May 05, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ABBV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (30.864) is very high in comparison to the industry average of (5.632). P/E Ratio (66.456) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.499) is also within normal values, averaging (3.004). Dividend Yield (0.033) settles around the average of (0.161) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
---|---|---|---|---|
ABBV | 100% | +0.47% | ||
PFE - ABBV | 54% Loosely correlated | -0.13% | ||
AMGN - ABBV | 49% Loosely correlated | +0.10% | ||
NVS - ABBV | 46% Loosely correlated | +0.81% | ||
JNJ - ABBV | 44% Loosely correlated | +0.12% | ||
GILD - ABBV | 41% Loosely correlated | -1.06% | ||
More |